69.5 F
Fort Worth
Tuesday, November 24, 2020
Health Care Rethinking Alzheimer’s treatment
Health Care Rethinking Alzheimer’s treatment

Rethinking Alzheimer’s treatment

Other News

A look at big issues on Supreme Court’s agenda

Some of the issues either already on the Supreme Court's docket when it begins its new session or likely to be before the justices...

Wall Street posts solid gains after surge in corporate deals

By ALEX VEIGA and DAMIAN J. TROISE AP Business Writers Wall Street kicked off the week with a broad rally Monday, clawing back much of...

Tarrant County ranks low in work-from-home study by NAR

North Texas ranks pretty high in the “Work from Home” category, according to a just-released study by the National Association of Realtors. But Tarrant...

Commentary: Universities and COVID-19: Charting turbulent times

Ray Perryman As the COVID-19 pandemic emerged this spring, college campuses across the United States swiftly sent students home in droves and switched to...

Investors flocked back to Biogen last week after the drugmaker said its potential Alzheimer’s treatment may have new life. But many on Wall Street preach caution. Company shares had plunged in March after Biogen stopped two studies of a drug called aducanumab when partial results suggested it was not likely to succeed. But on Oct. 22 Biogen made a surprise announcement that it will seek regulatory approval to sell the drug, and the stock shot up. Biogen said a subsequent data analysis suggested that the drug, when delivered at high doses, helped reduce a decline of thinking skills in patients

with early stage Alzheimer’s. Any drug that treats Alzheimer’s could generate billions in revenue, analysts say. The problem is that it’s far from clear that aducanumab does that effectively enough to get approved. Most analysts who cover the company have kept a “hold” rating on the shares instead of recommending that investors buy. Canaccord Genuity’s Sumant Kulkarni said he needs to see more data, expected to be presented at a medical meeting in early December, before he decides whether to change his recommendation. Kulkarni gives the drug a 20% chance of getting approved.


Oh hi there 👋
It’s nice to meet you.

Sign up to receive awesome content in your inbox.

We don’t spam! Read our privacy policy for more info.

Latest News

3rd major COVID-19 vaccine shown to be effective and cheaper

By DANICA KIRKA Associated PressLONDON (AP) — Drugmaker AstraZeneca said Monday that late-stage trials showed its COVID-19 vaccine is highly effective, buoying the prospects...

Left for dead, twice, RadioShack gets another shot online

SILVER SPRING, Md. (AP) — RadioShack, a fixture at the mall for decades, has been pulled from brink of death, again. It’s the most prized...

These health care workers will be first in line for a COVID-19 vaccine

Health care workers will be the first people in Texas to receive a COVID-19 vaccine once one receives emergency approval from the U.S. government,...

Tarrant County reports 1,537 new COVID cases on Sunday and 6 deaths

Tarrant County Public Health reported 1,537 new cases on Sunday, Nov. 22 and six deaths. “It took 90 days to reach 10,000 cases in June....

Employers start sending workers shopping for health coverage

Instead of offering one or more options, some companies are turning health insurance shopping over to employees. A federal rule change last year stoked this...